<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rpmj</journal-id><journal-title-group><journal-title xml:lang="ru">Research'n Practical Medicine Journal</journal-title><trans-title-group xml:lang="en"><trans-title>Research and Practical Medicine Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2410-1893</issn><publisher><publisher-name>"QUASAR", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.17709/2409-2231-2016-3-2-4</article-id><article-id custom-type="elpub" pub-id-type="custom">rpmj-135</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>ПРОГНОСТИЧЕСКАЯ ЗНАЧИМОСТЬ СОДЕРЖАНИЯ БЕЛКА nm23 В ОПУХОЛЯХ БОЛЬНЫХ КОЛОРЕКТАЛЬНЫМ РАКОМ</article-title><trans-title-group xml:lang="en"><trans-title>PROGNOSTIC SIGNIFICANCE OF nm23 PROTEIN IN THE TUMORS OF PATIENTS WITH COLORECTAL CANCER</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Головков</surname><given-names>Д. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Golovkov</surname><given-names>D. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Головков Дмитрий Анатольевич – доктор медицинских наук, заведующий колопроктологическим отделением </p><p>Для корреспонденции: БУЗ ВО «Воронежский областной клинический онкологический диспансер» Адрес: 394036, Россия, Воронеж, ул. Вайцеховского, 4 E-mail: dagolov@mail.ru</p></bio><bio xml:lang="en"><p>Dmitriy A. Golovkov – MD, head of coloproctological department </p><p>For correspondence: BOH «Voronezh regional clinical oncological dispensary» Address: 4, ul. Vaitsekhovskogo,Voronezh, 394036, Russia E-mail: dagolov@mail.ru</p></bio><email xlink:type="simple">dagolov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мошуров</surname><given-names>И. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Moshurov</surname><given-names>I. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мошуров Иван Петрович – кандидат медицинских наук, главный врач БУЗ ВО «Воронежский областной клинический онкологический диспансер», заведующий кафедрой онкологии ИПДО «Воронежский государственный медицинский университет им. Н.Н. Бурденко» </p></bio><bio xml:lang="en"><p>Ivan P. Moshurov – PhD, head doctor of BOH «Voronezh regional clinical oncological dispensary», Head of department of oncology</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Делекторская</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Delektorskaya</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Делекторская Вера Владимировна – доктор медицинских наук, заведующая лабораторией гистохимии и электронной микроскопии</p></bio><bio xml:lang="en"><p>Vera V. Delektorskaya – MD, head of the laboratory of histochemistry and electron microscopy</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Суховерков</surname><given-names>Д. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Sukhoverkov</surname><given-names>D. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Суховерков Дмитрий Валентинович – врач-онколог</p></bio><bio xml:lang="en"><p>Dmitriy V. Sukhoverkov – oncologist microscopy</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Быковцев</surname><given-names>М. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Bykovtsev</surname><given-names>M. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Быковцев Максим Борисович – врач-онколог</p></bio><bio xml:lang="en"><p>Maxim B. Bykovtsev – oncologist l&gt; microscopy</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мошуров</surname><given-names>Р. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Moshurov</surname><given-names>R. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мошуров Руслан Иванович – ординатор</p></bio><bio xml:lang="en"><p>Ruslan I. Moshurov – resident</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Петров</surname><given-names>Л. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Petrov</surname><given-names>L. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Петров Леонид Олегович – кандидат медицинских наук, научный сотрудник абдоминального отделения span&gt; » </p><p> </p></bio><bio xml:lang="en"><p>Leonid O. Petrov – PhD, researcher of abdominal department</p></bio><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Воронежский областной клинический онкологический диспансер, Воронеж</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Voronezh State Medical University named after N.N. Burdenko, Voronezh</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Воронежский областной клинический онкологический диспансер; &#13;
Воронежский государственный медицинский университет им. Н.Н. Бурденко, Воронеж</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Voronezh State Medical University named after N.N. Burdenko, Voronezh</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Российский онкологический научный центр имени Н. Н. Блохина, Москва</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.N. Blokhin Russian Cancer Research Center</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>Московский научно-исследовательский онкологический институт имени П. А. Герцена - филиал ФГБУ «НМИРЦ» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Р. Hertsen Moscow Oncology Research Institute - Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>01</day><month>07</month><year>2016</year></pub-date><volume>3</volume><issue>2</issue><fpage>31</fpage><lpage>36</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Головков Д.А., Мошуров И.П., Делекторская В.В., Суховерков Д.В., Быковцев М.Б., Мошуров Р.И., Петров Л.О., 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="ru">Головков Д.А., Мошуров И.П., Делекторская В.В., Суховерков Д.В., Быковцев М.Б., Мошуров Р.И., Петров Л.О.</copyright-holder><copyright-holder xml:lang="en">Golovkov D.A., Moshurov I.P., Delektorskaya V.V., Sukhoverkov D.V., Bykovtsev M.B., Moshurov R.I., Petrov L.O.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpmj.ru/rpmj/article/view/135">https://www.rpmj.ru/rpmj/article/view/135</self-uri><abstract><sec><title>Цель</title><p>Цель. Изучение экспрессии белка nm 23 в первичных и вторичных очагах РТК с учетом клинико-морфологических особенностей заболевания и возможности прогнозирования риска отдаленного метастазирования.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В исследование включен послеоперационный материал 264 больных РТК I–IVстадий опухолевого процесса. Иммуногистохимическое окрашивание выполнено биотин-стрептавидиновым иммунопероксидазным методом на парафиновых срезах ткани первичных опухолей толстой кишки и их метастазов в лимфатических узлах и печени с использованием антител к белку nm23 (H‑1 и H‑2) (“Dako”, Дания).</p><p>Результаты оценивались полуколичественным способом с учетом интенсивности окрашивания и количества антиген-позитивных клеток и локализации иммунореактивности в раковых клетках. Результаты. При иммуногистохимическом исследовании первичных опухолей толстой кишки повышенное накопление белка nm23 наблюдалось в 53,4% (141/264) исследованных случаев. В метастазах РТК сохранялись основные закономерности экспрессии маркера, свойственные соответствующим первичным опухолям. Кривые выживаемости, вычисленные по методу Kaplan-Meyer, показывают, что пациенты с nm23‑позитивным окрашиванием опухолей демонстрируют более низкий показатель 5‑летней общей выживаемости, чем больные с негативной иммунореактивностью в опухоли. Показатели БРВ у больных РТК также ухудшались при nm23‑негативном статусе опухолей по сравнению с nm23‑позитивным статусом.</p></sec><sec><title>Заключение</title><p>Заключение. Гиперэкспрессия белка nm 23 часто выявлялась в первичных метастазирующих опухолях ТК и их метастазах в печени и была связана с высоким риском развития отдаленных метастазов, а также с неблагоприятным исходом заболевания и с ухудшением послеоперационной общей и безрецидивной выживаемости больных РТК. Высокий уровень экспрессии данного маркера являлся признаком неблагоприятного прогноза для больных РТК.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Purpose</title><p>Purpose. Study of expression of protein nm23 inprimary and secondary foci of colorectal cancer (CRC) taking in consideration the clinical and morphological features of the disease and the possibility of predicting the risk of distant metastases.</p></sec><sec><title> Material and methods</title><p> Material and methods. The study included postoperative material of 264 CRC patients with I–IV stages of cancer. Immunohistochemical staining performed by biotin-streptavidin immunoperoxidase method on the paraffin tissue sections of primary colon tumors and their metastases in lymph nodes and liver using antibodies against nm23 protein (H‑1 and H‑2) (“Dako”, Denmark). The results were evaluated by semiquantitative method based on the staining intensity and the number of antigen-positive cells and localization of immunoreactivity in cancer cells.</p></sec><sec><title>Results</title><p>Results. During the immunohistochemical study of primary tumors of the colon the increase of the accumulation of nm23 protein was observed in 53.4% (141/264) studied cases. In nmtastasis of CRC the main patterns of expression of a marker characteristic of the corresponding primary tumors was preserved. Survival curves, computed according to the method of Kaplan-Meyer showed that patients with nm23‑positive staining of tumors show a lower 5‑year overall survival than patients with negative immunoreactivity in the tumor. Indicators of disease-free survival in patients with CRC also deteriorated in nm23‑negative status of tumors compared to nm23‑positive status.</p></sec><sec><title>Conclusion</title><p>Conclusion. The overexpression of nm 23 protein were freqently detected in metastasizing primary tumors of colon and their liver metastases and was associated with a high risk of developing distant metastases, and poor outcome of the disease and the deterioration of the postoperative overall and disease-free survival of CRC patients. A high expression level of this marker is a sign of unfavorable prognosis for CRC patients.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>белок nm23</kwd><kwd>метастазы</kwd><kwd>прогноз</kwd><kwd>рак толстой кишки</kwd></kwd-group><kwd-group xml:lang="en"><kwd>protein nm23</kwd><kwd>metastasis</kwd><kwd>prognosis</kwd><kwd>colorectal cancer</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Пожарисский К. М., Леенман Е. Е. Прогностическое и предсказательное значение иммуногистохимических маркеров. Руководство по иммуногистохимической диагностике опухолей человека. Ред. Петров С. В. и Райхлин Н. Т. Казань, 2004.</mixed-citation><mixed-citation xml:lang="en">Pozharisskii K. M., Leenman E. E. Prognosticheskoe i predskazatel'noe znachenie immunogistokhimicheskikh markerov. Rukovodstvo po immunogistokhimicheskoi diagnostike opukholei cheloveka. Ed by Petrov S. V. i Raikhlin N. T. Kazan', 2004. (Russian).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Brenner A. S., Thebo J. S., Senagore A.J., Duepree H.J., Gramlich T., Ormsby A., et al. Analysis of both NM23 Н1 and NM23 H2 expression identifies "at-risk" patients with colorectal cancer. Am Surg. 2003; 69 (3): 203–208.</mixed-citation><mixed-citation xml:lang="en">Brenner A. S., Thebo J. S., Senagore A.J., Duepree H.J., Gramlich T., Ormsby A., et al. Analysis of both NM23 Н1 and NM23 H2 expression identifies "at-risk" patients with colorectal cancer. Am Surg. 2003; 69 (3): 203–208.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Gao Q. L., Ma D., Meng L., Wang S. X., Wang C. Y., Lu Y. P., et al. Association between Nm23 H1 gene expression and metastasis of ovarian carcinoma. Ai Zheng. 2004; 23 (6): 650–654.</mixed-citation><mixed-citation xml:lang="en">Gao Q. L., Ma D., Meng L., Wang S. X., Wang C. Y., Lu Y. P., et al. Association between Nm23 H1 gene expression and metastasis of ovarian carcinoma. Ai Zheng. 2004; 23 (6): 650–654.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Garinis G.A., Manolis E.N., Spanakis N. E. Patrinos G. P., Peros G., Menounos P.G. High frequency of concomitant nm23 H1 and E cadherin transcriptional inactivation in primary non-inheriting colorectal carcinomas. J Mol Med. 2003; 81 (4): 256–263.</mixed-citation><mixed-citation xml:lang="en">Garinis G.A., Manolis E.N., Spanakis N. E. Patrinos G. P., Peros G., Menounos P.G. �igh frequency of concomitant nm23 H1 and E cadherin transcriptional inactivation in primary non-inheriting colorectal carcinomas. J Mol Med. 2003; 81 (4): 256–263.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Nanashima A., Yamaguchi H., Sawai T., Yamaguchi E., Kidogawa H., Matsuo S., et al. Prognostic factors in hepatic metastases of colorectal carcinoma: immunohistochemical analysis of tumour biological factors. Dig Dis Sci. 2001; 46 (8): 1623–1628.</mixed-citation><mixed-citation xml:lang="en">Nanashima A., Yamaguchi H., Sawai T., Yamaguchi E., Kidogawa H., Matsuo S., et al. Prognostic factors in hepatic metastases of colorectal carcinoma: immunohistochemical analysis of tumour biological factors. Dig Dis Sci. 2001; 46 (8): 1623–1628.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Bosnar M.H., De Gunzburg J., Bago R, Brecević L., Weber I., Pavelić J. Subcellular localization of A and B Nm23/NDPK subunits. Exp Cell Res. 2004; 298 (1): 275–284.</mixed-citation><mixed-citation xml:lang="en">Bosnar M.H., De Gunzburg J., Bago R, Brecević L., Weber I., Pavelić J. Subcellular localization of A and B Nm23/NDPK subunits. Exp Cell Res. 2004; 298 (1): 275–284.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Dursun A., Akyurek N., Gunel N., Yamaç D. Prognostic implication of nm23H1 expression in colorectal carcinomas. Pathology. 2002; 34 (5): 427–432.</mixed-citation><mixed-citation xml:lang="en">Dursun A., Akyurek N., Gunel N., Yamaç D. Prognostic implication of nm23H1 expression in colorectal carcinomas. Pathology. 2002; 34 (5): 427–432.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Forte A., D'Urso A., Gallinaro L. S. NM23 expression as prognostic factor in colorectal carcinoma. G Chir. 2002; 23 (3): 61–63.</mixed-citation><mixed-citation xml:lang="en">Forte A., D'Urso A., Gallinaro L. S. NM23 expression as prognostic factor in colorectal carcinoma. G Chir. 2002; 23 (3): 61–63.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Hayer J., Engel M., Seifert M., Seitz G, Welter C. Overexpression of nm23 H4 RNA in colorectal and renal tumours. Anticancer Res. 2001; 21 (4A): 2821–2825.</mixed-citation><mixed-citation xml:lang="en">Hayer J., Engel M., Seifert M., Seitz G, Welter C. Overexpression of nm23 H4 RNA in colorectal and renal tumours. Anticancer Res. 2001; 21 (4A): 2821–2825.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Terada R., Yasutake T., Nakamura S., Hisamatsu T., Sawai T., Yamaguchi H., et al. Clinical significance of nm 23 expression and chromosome 17 numerical aberrations in primary gastric cancer. Med Oncol. 2002; 19 (4): 239–248.</mixed-citation><mixed-citation xml:lang="en">Terada R., Yasutake T., Nakamura S., Hisamatsu T., Sawai T., Yamaguchi H., et al. Clinical significance of nm 23 expression and chromosome 17 numerical aberrations in primary gastric cancer. Med Oncol. 2002; 19 (4): 239–248.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
